Cabozantinib in Men With Castration-Resistant Prostate Cancer

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT01703065
Phase
PHASE2
Status
Terminated

Conditions

  • Adenocarcinoma of the Prostate
  • Castration-resistant Prostate Cancer
  • Recurrent Prostate Cancer
  • Stage III Prostate Cancer
  • Stage IV Prostate Cancer

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Jun 18, 2013
Status verified
Nov 2018
Primary completion
Feb 2, 2015
Completion
Sep 18, 2015

Study Design

Enrollment
9 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib in metastatic CRPC
    Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
  • Experimental: Cabozantinib in non-metastatic CRPC
    Non-Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Change in Urinary N-telopeptide (uNTX) as a Marker of Bone Metabolism in Non-metastatic Patients [ Time Frame: Baseline and 6 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Seattle Cancer Care Alliance/University of WashingtonSeattleWashington98109-

Find similar trials in Seattle, WA

By research site
Seattle Cancer Care Alliance/University of Washington· Seattle, WA

Related Studies